Home HRCompany Profiles The Board of Oslo Børs approves Cortendo for listing

The Board of Oslo Børs approves Cortendo for listing

by admin

oslo bors22/10/2014 – At its meeting on 22 October 2014, the Board of Directors of Oslo Børs resolved to admit the shares in Cortendo AB to listing on Oslo Axess.

The Board stipulated that the company prior to the first day of listing must publish an approved prospectus and raise at least NOK 48 million of new capital through its planned primary share issue.

The Board authorised the Chief Executive Officer of Oslo Børs to fix the date of the first day of listing, which is to be no later than5 December 2014.

About Cortendo:
Cortendo AB is a biopharmaceutical company with a strategic focus to be the global leader in developing and commercializing products within Orphan Diseases and Endocrinology Disorders. Cortendo aims to be a frontrunner within cortisol inhibition, with its drug candidate COR-003 in a Phase 3 global clinical trial for the treatment of Cushing’s Syndrome. Cortendo intends to independently commercialize its Orphan/Endocrine assets and partner non-strategic product opportunities, such as diabetes.

You may also like

Leave a Comment